AllHome bags ₹200 cr Series B at ₹2,000 cr valuation to scale building materials play
PharmEasy founders' home-and-interiors venture, backed by Bessemer, will deploy capital across experience centres, manufacturing and category expansion. At ₹400 cr ARR with 18-20% EBITDA margins, it targets ₹1,000 cr revenue over next 4-6 quarters in a fragmented $50 bn market.
What happened
AllHome, a tech-led building materials and interior products startup from PharmEasy founders, raised ₹200 crore Series B led by Bessemer at ₹2,000 crore
Key facts
- ₹200 crore
- ₹2,000 crore valuation
- ₹400 crore ARR
- 18-20% EBITDA margin
- ₹1,000 crore revenue target
- $50 billion market
Why this matters
AllHome's funded push into manufacturing and category expansion could consolidate the fragmented building materials space—incumbents should evaluate partnership or acquisition windows before the 4-6 quarter ₹1,000 cr revenue target tightens valuations.
What to watch
- Revenue/EBITDA disclosure in MCA filings for FY25
- Senior hires in supply chain, manufacturing, or category heads
- Acquisition of a regional building-materials brand or factory
- Competitor funding rounds (Livspace, HomeLane, Nobroker Interiors)
- Real-estate-developer tie-ups for project-led B2B revenue
- Series C timing — if within 12 months, signals burn acceleration
- Map AllHome's experience-centre rollout pace vs HomeLane/Livspace footprint quarterly
- Track private-label SKU mix and gross-margin trajectory in any disclosed metrics
- Watch for tile/sanitaryware/modular kitchen category launches as M&A or partnership signals
- Benchmark ARR growth vs comparable Bessemer portfolio (Pepperfry trajectory) for pattern read